Nicotine and amyloid formation

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 248-257

  Zeng, Hong ^a   Zhang, Yongbo ^a   Peng, Li Jun ^a   Shao, Haiyan ^a   Menon, Nanda K ^c   Yang, Jing ^a   Salomon, Arthur R ^a   Freidland, Robert P ^b   Zagorski, Michael G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; A peptide; Nicotine; NMR

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; NICOTINE; PEPTIDE;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; BETA SHEET; CHOLINERGIC ACTIVITY; CIGARETTE SMOKING; CONFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

EID: 0035251678     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01111-2     Document Type: Review

References (57)

1. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
2. Solution structures of β peptide and its constituent fragments: Relation to amyloid deposition
3. Methodological advances in protein NMR
4. Pharmacology of nicotine: Addition and therapeutics
5. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma
6. Efficient high yield reversed-phase HPLC separations of amyloid precursor polypeptide C-terminal fragments
7. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?
8. NMR in drug design
9. Prospects for pharmacological intervention in Alzheimer disease
10. In vitro growth of Alzheimer's disease β-amyloid plaques displays first-order kinetcis
11. Epidemiology and neurobiology of the multiple determinants of Alzheimer's disease
12. Soluble amyloid aβ-(1-40) exists as a stable dimer at low concentrations
13. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity
14. High-throughput nuclear magnetic resonance-based screening
15. Amyloid, the presenilins and Alzheimer's disease
16. Methods to study membrane protein structure in solution
17. Aggregation and secondary structure of synthetic amyloid βa4 peptides of Alzheimer's disease
18. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide
19. Fibrillogenesis of Alzheimer Aβ peptides studied by fluorescence energy transfer
20. The toxicity in vitro of β-amyloid protein
21. Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide
22. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
23. Nuclear and cytoplasmic localization of the β-amyloid peptide (1-43) in transfected 293 Cells
24. Pulsed field gradient multi-dimensional nmr methods for the study of protein structure and dynamics in solution
25. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity
26. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid a4/β protein
27. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease
28. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins
29. 1H NMR of aβ amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence
30. Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease
31. Soluble multimeric Alzheimer β(1-40) pre-amyloid complexes in dilute solution
32. Structural analysis of Alzheimer's β(1-40) amyloid: Protofilament assembly of tubular fibrils
33. Solution structure model of residues 1-28 of the amyloid β-peptide when bound to micelles
34. Do inhibitors of β-amyloid aggregation also inhibit the aggregation of other amyloid-forming peptides?
35. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity
36. Structure-activity analysis of β-amyloid peptides: Contributions of the β25-35 region to aggregation and neurotoxicity
37. Morphology and toxicity of aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
38. Nicotine inhibits amyloid formation by the β-peptide
39. Mechanisms of neurotoxicity with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer's disease. A critical appraisal
40. Transthyretin sequesters amyloid β protein and prevents amyloid formation
41. Translating cell biology into therapeutic advances in Alzheimer's disease
42. The origins of Alzheimer disease: A is for amyloid
43. Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease
44. Amyloid Aβ(1-40) and Aβ(1-42) adopt remarkably stable and random extended structures in water solution at physiological ph
45. Discovering high-affinity ligands for proteins: SAR by NMR
46. Secondary structure of β-amyloid peptide correlates with toxicity in vitro
47. Solution structure of residues 1-28 of the amyloid β-peptide
48. Structural and kinetic features of amyloid β-protein fibrillogenesis
49. Interaction of Alzheimer β-amyloid peptide (1-40) with lipid membranes
50. Beta-amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology
51. The levels of soluble versus insoluble brain abeta distinguish Alzheimer's disease from normal and pathologic aging
52. Evidence that Aβ42 is the real culprit in Alzheimer's disease
53. The Molecular mechanisms of amyloidosis in Alzheimer's disease
54. Methodological and chemical factors affecting amyloid β peptide amyloidogenicity
55. Nicotine modulates the neurotoxic effect of β-amyloid protein (25-35) in hippocampal cultures